Overexpression of COX-2 and LMP1 are correlated with lymph node in Tunisian NPC patients

Oral Oncology

Volumn 44, Issue 7, 2008, Pages 710-715

  Fendri, Ali ^a   Khabir, Abdelmajid ^b   Hadhri Guiga, Boutheina ^a   Sellami Boudawara, Tahia ^b   Ghorbel, Abdelmoonem ^b   Daoud, Jamel ^b   Frikha, Mounir ^b   Jlidi, Rachid ^c   Gargouri, Ali ^a   Mokdad Gargouri, Raja ^a  

^a CENTRE DE BIOTECHNOLOGIE DE SFAX   (Tunisia)

^b HABIB BOURGUIBA HOSPITAL   (Tunisia)

^c EPS Habib Bourguiba   (Tunisia)

Author keywords

Cyclooxygenase 2; Latent membrane protein 1; Nasopharyngeal carcinoma; Overexpression

Indexed keywords

CYCLOOXYGENASE 2; LATENT MEMBRANE PROTEIN 1; MESSENGER RNA;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE; MALE; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN INDUCTION; SCHOOL CHILD; TUMOR BIOPSY; TUMOR CELL; TUNISIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CHILD; CYCLOOXYGENASE 2; FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM PROTEINS; NEOPLASM STAGING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; UP-REGULATION; YOUNG ADULT;

EID: 45249110201     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2007.09.006     Document Type: Article

References (35)

1. Dubois R.N., Abramson S.B., Crofford L., Gupta R.A., Simon L.S., Van De Putte L.B., et al. Cyclooxygenase in biology and disease. FASEB J 12 (1998) 1063-1073
2. Zha S., Yegnasubramanian V., Nelson W.G., Isaacs W.B., and De Marzo A.M. Cyclooxygenases in cancer: progress and perspective. Cancer Lett 215 (2004) 1-20
3. Eberhart C.E., Coffey R.J., Radhika A., Giardiello F.M., Ferrenbach S., and DuBois R.N. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107 (1994) 1183-1188
4. Half E., Tang X.M., Gwyn K., Sahin A., Wathen K., and Sinicrope F.A. Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res 62 (2002) 1676-1681
5. Hasturk S., Kemp B., Kalapurakal S.K., Kurie J.M., Hong W.K., and Lee J.S. Expression of cyclooxygenase-1 and cyclooxygenase-2 in bronchial epithelium and non small cell lung carcinoma. Cancer 94 (2002) 1023-1031
6. Komhoff M., Guan Y., Shappell H.W., Davis L., Jack G., Shyr Y., et al. Enhanced expression of cyclooxygenase-2 in high grade human transitional cell bladder carcinomas. Am J Pathol 157 (2000) 29-35
7. Oshima M., Dinchuk J.E., Kargman S.L., Oshima H., Hancock B., Kwong E., et al. Suppression of intestinal polyposis in Apc delta 716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87 (1996) 803-809
8. Liu C.H., Chang S.H., Narko K., et al. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 21 (2001) 18563-18569
9. Tsujii M., Kawano S., Tsuji S., Sawaoka H., Hori M., and DuBois R.N. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93 (1998) 705-716
10. Murata H., Kawano S., Tsuji S., et al. Cyclooxygenase-2 overexpression enhances lymphatic invasion and metastasis in human gastric carcinoma. Am J Gastroenterol 2 (1999) 451-455
11. Yao M., Kargman S., Lam E.C., Kelly C.R., Zheng Y., and Luk P. Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice. Cancer Res 3 (2003) 586-592
12. Jones M.K., Wang H., Peskar B.M., Levin E., Itani R.M., Sarfeh I.J., et al. Inhibition of angiogenesis by NSAIDs: molecular mechanisms and clinical implications. Nat Med 5 (1999) 1418-1423
13. Nicholls J.M., Agathanggelou A., Fung K., Zeng X., and Niedobitek G. The association of squamous cell carcinomas of the nasopharynx with Epstein-Barr virus shows geographical variation reminiscent of Burkitt's lymphoma. J Pathol 183 (1997) 164-168
14. Busson P., Keryer C., Ooka T., and Corbex M. EBV-associated nasopharyngeal carcinomas: from epidemiology to virus-targeting strategies. Trends Microbiol 12 (2004) 356-360
15. Kammoun M., Vogt-Hoerner G., and Mourali N. Tumors of the nasopharynx in Tunisia: an anatomic and clinical study based on 143 cases. Cancer 33 (1974) 184-191
16. Khabir A., Sellami A., Sakka M., Ghorbel A.M., Daoud J., Frikha M., et al. Contrasted frequencies of p53 accumulation in the two age groups of North African nasopharyngeal carcinomas. Clin Cancer Res 6 (2000) 3932-3936
17. Daoud J., Toumi N., Bouaziz M., Ghorbel A., Jlidi R., Drira M.M., et al. Nasopharyngeal carcinoma in childhood and adolescence: analysis of a series of 32 patients treated with combined chemotherapy and radiotherapy. Eur J Cancer 39 (2003) 2349-2354
18. Young L.S., Dawson C.W., Clark D., Rupani H., Busson P., Tursz T., et al. Epstein-Barr virus gene expression in nasopharyngeal carcinoma. J Gen Virol 69 (1988) 1051-1065
19. Liebowitz D. Nasopharyngeal carcinoma: the Epstein-Barr virus association. Semin Oncol 21 (1994) 376-381
20. Raab-Traub N. Epstein-Barr virus in the pathogenesis of NPC. Semin Cancer Biol 12 (2002) 431-441
21. Khabir A., Karray H., Rodriguez S., Rosé M., Daoud J., Frikha M., et al. EBV latent membrane protein 1 abundance correlates with patient age but not with metastatic behavior in north African nasopharyngeal carcinomas. Virol J 2 (2005) 1-7
22. Murono S., Inoue H., Tanabe T., et al. Induction of cyclooxygenase-2 by Epstein-Barr virus Latent membrane Protein 1 is involved in vascular endothelial growth factor production in nasopharyngeal carcinoma cells. Proc Natl Acad Sci USA 98 (2001) 6905-6910
23. Chen W.C., McBride W.H., Chen S.M., et al. Prediction of poor survival by cyclooxygenase-2 in patients with T4 nasopharyngeal cancer treated by radiation therapy: clinical and in vitro studies. Head Neck 6 (2005) 503-512
24. Chan C.L., Ma M.Y., Hui E.P., Wong S.C.C., Mo F.K.F., Leung S.F., et al. Cyclooxygenase-2 expression in advanced nasopharyngeal carcinoma: a prognostic evaluation and correlation with hypoxia inducible factor 1a and vascular endothelial growth factor. Oral Oncol 4 (2006) 1010-1016
25. Tan K.B., and Putti T.C. Cyclooxygenase-2 expression in nasopharyngeal carcinoma: immunohistochemical findings and potential implications. J Clin Pathol 58 (2005) 535-538
26. Wolff H., Saukkonen K., Anttila S., Karjalainen A., Vainio H., and Ristimaki A. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 58 (1998) 4997-5001
27. Hwang D., Scollard D., Byrne J., and Levine E. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 90 (1998) 455-460
28. Zimmermann K.C., Sarbia M., Weber A.A., Borchard F., Gabbert H.E., and Schror K. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res 59 (1999) 198-204
29. Chan G., Boyle J.O., Yang E.K., Zhang F., Sacks P.G., Shah J.P., et al. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res 59 (1999) 991-994
30. Sheehan K.M., Sheahan K., O'Donoghue D.P., et al. The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA 13 (1999) 1254-1257
31. Costa C., Soares R., Reis-Filho J.S., Leitao D., Amendoeira I., and Schmitt F.C. Cyclooxygenase -2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. J Clin Pathol 55 (2002) 429-434
32. Subbaramaiah K., and Dannenberg A.J. Cyclooxygenase-2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci 24 (2003) 96-102
33. Sheng H., Shao J., Kirkland S.C., Isakson P., Coffey R.J., Morrow J., et al. Inhibition of Human Colon Cancer Cell Growth by Selective Inhibition of Cyclooxygenase-2. J Clin Invest 99 (1997) 2254-2259
34. Steinbach G., Lynch P.M., Phillips R.K., Wallace M.H., Hawk E., Gordon G.B., et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342 (2000) 1946-1952
35. Chen P., and Long Q. Effects of cyclooxygenase-2 inhibitors on biological traits of nasopharyngeal carcinoma cells. Acta Pharmacol Sin 7 (2004) 943-949